We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

90 hedge funds and large institutions have $196M invested in Eiger BioPharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 35 increasing their positions, 26 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

408% more call options, than puts

Call options by funds: $4.08M | Put options by funds: $803K

35% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 26

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less funds holding

Funds holding: 94 → 90 (-4)

5% less capital invested

Capital invested by funds: $207M → $196M (-$11.1M)

31% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 13

Holders
90
Holders Change
-4
Holders Change %
-4.26%
% of All Funds
1.57%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
9
Increased
35
Reduced
26
Closed
13
Calls
$4.08M
Puts
$803K
Net Calls
+$3.28M
Net Calls Change
+$958K

Top Buyers

Rank Fund Capital Flow
1
Ameriprise
Ameriprise
Minnesota
+$8.86M
2
6CM
683 Capital Management
New York
+$2.22M
3
BCM
Bridgeway Capital Management
Texas
+$1.07M
4
Morgan Stanley
Morgan Stanley
New York
+$506K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$477K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$7.4M
2
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$3.47M
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$1.36M
4
Two Sigma Investments
Two Sigma Investments
New York
-$1.2M
5
Millennium Management
Millennium Management
New York
-$1.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIC
101
Ameritas Investment Company
Nebraska
– -$3.39K -13 Closed
SFS
102
Sowell Financial Services
Arkansas
– -$1K -3 Closed
1 2 3 4
5

EIGR Hedge Fund Activity: Q2 2021 in Review

90 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2021, worth a combined $196M — down 5.4% from $207M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of EIGR and 9 opened new positions — a net loss of 4 holders — while 26 trimmed existing stakes and 35 added.

The largest buyer was Ameriprise, adding an estimated $8.86M. The largest seller was Citadel Advisors, exiting entirely with an estimated $7.4M sold.

  • 90 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2021, down from 94 in Q1 2021.
  • Funds reported $196M of Eiger BioPharmaceuticals, Inc. stock for Q2 2021, down 5.4% quarter-over-quarter.
  • 9 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2021 and 13 closed out, a net change of -4 holders.
  • The largest Eiger BioPharmaceuticals, Inc. buyer in Q2 2021 was Ameriprise, an estimated $8.86M added.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2021 was Citadel Advisors, an estimated $7.4M sold.

Based on aggregated 13F filings for Q2 2021.